Vol. 4 No. 7 (2024)
Reimbursement Reviews

Dostarlimab (Jemperli)

decorative image of the issue cover

Published July 24, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses dostarlimab (JEMPERLI), 500mg/10 mL (50 mg/mL), 500 mg every 3 weeks for 6 cycles followed by 1,000 mg every 6 weeks, solution for IV infusion.
  • Indication: In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy.